CONTEXT: Investigating the impact of hyperglycemia on pancreatic endocrine function promotes our understanding of the pathophysiology of hyperglycemia-related disease. OBJECTIVE: The objective of the study was to test the hypothesis that experimental hyperglycemia impairs insulin and glucagon secretion. DESIGN: A randomized, crossover in healthy controls, compared with type 2 diabetic patients. SETTING: The study was conducted at a university hospital. PARTICIPANTS: Normal glucose-tolerant subjects (n = 10) and patients with type 2 diabetes (n = 10), individually matched by age, sex, and body mass index. INTERVENTIONS:Normal glucose-tolerant subjects underwent 24 h of experimental hyperglycemia (+5.4 mm above basal). Subjects with type 2 diabetes did not undergo an intervention. MAIN OUTCOME MEASURES: Insulin secretion, glucagon secretion, insulin sensitivity, disposition index, and endogenous glucose production (via [6,6-(2)H(2)]glucose infusion) were measured during hyperglycemic clamps combined with infusion of glucagon-like peptide (GLP)-1(7-36) (0.5 pmol/kg · min) and injection of arginine (5 g). RESULTS:Insulin secretion was correlated with glucagon suppression in subjects with normal glucose tolerance only. Individuals with type 2 diabetes had lower insulin sensitivity (-33 ± 11%) and insulin secretory responses to glucose, GLP-1, and arginine (-40 ± 11, -58 ± 7, and -36 ± 13%, respectively) and higher plasma glucagon and endogenous glucose production compared with normal glucose-tolerant subjects (all P < 0.05). After 24 h of experimental hyperglycemia, insulin sensitivity (-29 ± 10%), disposition index (-24 ± 16%), and GLP-1- (-19 ± 7%) and arginine-stimulated (-15 ± 10%) insulin secretion were decreased in normal glucose-tolerant subjects (all P < 0.05). However, plasma glucagon responses were not affected. Furthermore, experimental hyperglycemia abolished the correlation between insulin secretion and glucagon suppression. CONCLUSIONS: Experimental hyperglycemia impaired pancreatic β-cell function but did not acutely impair α-cell glucagon secretion in normal glucose-tolerant subjects.
RCT Entities:
CONTEXT: Investigating the impact of hyperglycemia on pancreatic endocrine function promotes our understanding of the pathophysiology of hyperglycemia-related disease. OBJECTIVE: The objective of the study was to test the hypothesis that experimental hyperglycemia impairs insulin and glucagon secretion. DESIGN: A randomized, crossover in healthy controls, compared with type 2 diabeticpatients. SETTING: The study was conducted at a university hospital. PARTICIPANTS: Normal glucose-tolerant subjects (n = 10) and patients with type 2 diabetes (n = 10), individually matched by age, sex, and body mass index. INTERVENTIONS: Normal glucose-tolerant subjects underwent 24 h of experimental hyperglycemia (+5.4 mm above basal). Subjects with type 2 diabetes did not undergo an intervention. MAIN OUTCOME MEASURES: Insulin secretion, glucagon secretion, insulin sensitivity, disposition index, and endogenous glucose production (via [6,6-(2)H(2)]glucose infusion) were measured during hyperglycemic clamps combined with infusion of glucagon-like peptide (GLP)-1(7-36) (0.5 pmol/kg · min) and injection of arginine (5 g). RESULTS:Insulin secretion was correlated with glucagon suppression in subjects with normal glucose tolerance only. Individuals with type 2 diabetes had lower insulin sensitivity (-33 ± 11%) and insulin secretory responses to glucose, GLP-1, and arginine (-40 ± 11, -58 ± 7, and -36 ± 13%, respectively) and higher plasma glucagon and endogenous glucose production compared with normal glucose-tolerant subjects (all P < 0.05). After 24 h of experimental hyperglycemia, insulin sensitivity (-29 ± 10%), disposition index (-24 ± 16%), and GLP-1- (-19 ± 7%) and arginine-stimulated (-15 ± 10%) insulin secretion were decreased in normal glucose-tolerant subjects (all P < 0.05). However, plasma glucagon responses were not affected. Furthermore, experimental hyperglycemia abolished the correlation between insulin secretion and glucagon suppression. CONCLUSIONS: Experimental hyperglycemia impaired pancreatic β-cell function but did not acutely impair α-cell glucagon secretion in normal glucose-tolerant subjects.
Authors: Michael A Hendley; Kendall P Murphy; Christopher Isely; Heather L Struckman; Prakasam Annamalai; R Michael Gower Journal: Biomaterials Date: 2019-06-19 Impact factor: 12.479
Authors: Stephanie von Holstein-Rathlou; Lucas D BonDurant; Lila Peltekian; Meghan C Naber; Terry C Yin; Kristin E Claflin; Adriana Ibarra Urizar; Andreas N Madsen; Cecilia Ratner; Birgitte Holst; Kristian Karstoft; Aurelie Vandenbeuch; Catherine B Anderson; Martin D Cassell; Anthony P Thompson; Thomas P Solomon; Kamal Rahmouni; Sue C Kinnamon; Andrew A Pieper; Matthew P Gillum; Matthew J Potthoff Journal: Cell Metab Date: 2015-12-24 Impact factor: 27.287
Authors: Edwin R Miranda; Vikram S Somal; Jacob T Mey; Brian K Blackburn; Edward Wang; Sarah Farabi; Kristian Karstoft; Ciaran E Fealy; Sangeeta Kashyap; John P Kirwan; Laurie Quinn; Thomas P J Solomon; Jacob M Haus Journal: Am J Physiol Endocrinol Metab Date: 2017-08-15 Impact factor: 4.310
Authors: Aurora Merovci; Andrea Mari; Carolina Solis-Herrera; Juan Xiong; Giuseppe Daniele; Alberto Chavez-Velazquez; Devjit Tripathy; Scheherezada Urban McCarthy; Muhammad Abdul-Ghani; Ralph A DeFronzo Journal: J Clin Endocrinol Metab Date: 2015-02-24 Impact factor: 5.958
Authors: Aurora Merovci; Carolina Solis-Herrera; Giuseppe Daniele; Roy Eldor; Teresa Vanessa Fiorentino; Devjit Tripathy; Juan Xiong; Zandra Perez; Luke Norton; Muhammad A Abdul-Ghani; Ralph A DeFronzo Journal: J Clin Invest Date: 2014-01-27 Impact factor: 14.808
Authors: Thomas P J Solomon; Steven K Malin; Kristian Karstoft; Sangeeta R Kashyap; Jacob M Haus; John P Kirwan Journal: J Clin Endocrinol Metab Date: 2013-08-21 Impact factor: 5.958
Authors: Aurora Merovci; Muhammad Abdul-Ghani; Andrea Mari; Carolina Solis-Herrera; Juan Xiong; Giuseppe Daniele; Devjit Tripathy; Ralph A DeFronzo Journal: J Clin Endocrinol Metab Date: 2016-01-14 Impact factor: 5.958
Authors: Aurora Merovci; Devjit Tripathy; Xi Chen; Ivan Valdez; Muhammad Abdul-Ghani; Carolina Solis-Herrera; Amalia Gastaldelli; Ralph A DeFronzo Journal: Diabetes Date: 2020-10-08 Impact factor: 9.461